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PURPOSE: Tumour epithelial vimentin expression is a marker of mesenchymal differentiation and may be a useful marker of carcinomas
with more aggressive behaviour. The aim of this study was to determine the extent and prognostic significance of vimentin expression
in pancreatic ductal adenocarcinomas.
METHODS: Vimentin expression was detected by immunohistochemistry on tissue microarrays of surgically resected pancreatic ductal
adenocarcinomas from 387 patients. The percentage of vimentin-immunolabelled neoplastic cells was correlated with outcome and
with clinico–pathological factors using the Kaplan–Meier method and Cox multivariate survival models.
RESULTS: In all, 45% of primary pancreatic adenocarcinomas contained neoplastic cells that expressed vimentin, and in 27.5% of the
cancers 410% of cells expressed vimentin. Vimentin expression was correlated with poor histological differentiation. By both uni-
and multivariate survival analysis, neoplastic vimentin expression (Po0.01, HR 1.52, 95% confidence interval 1.14–2.04) was an
indicator of a shorter postsurgical survival independent of other clinico–pathological variables.
CONCLUSION: The presence of vimentin-expressing tumour epithelial cells in surgically resected pancreatic adenocarcinomas
independently predicted a shorter postsurgical survival.
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Pancreatic adenocarcinoma is the fourth leading cause of cancer
death in the United States. Although there have been numerous
advances in our understanding of pancreatic cancer development
and progression in recent years, therapies for pancreatic cancer
generally still provide only modest benefit. Surgical resection is
currently the most effective treatment but is undertaken in only
B15–20% of patients highlighting the need for early detection
strategies. Even among patients with resectable pancreatic cancer
survival is poor, with o20% of patients alive at 5 years Among
patients undergoing pancreatic resection with curative intent, the
main prognostic factors are histological grade, resection margin
status, tumour size, location and lymph node metastasis (Winter
et al, 2006; Corsini et al, 2008; Herman et al, 2008; Goggins, 2011
(in press); Vincent et al, 2011 (in press)).
Although very useful, these pathological risk factors do not
sufficiently predict outcome and most of these prognostic factors
reflect tumour stage rather than tumour epithelial biology.
Multiple studies have attempted to identify markers that may
assist in predicting outcome after pancreatic cancer resection and
that may also provide clues as to biological mechanisms that
contribute to pancreatic cancer aggressiveness. For example,
mutations or loss of expression of tumour-suppressor proteins
expressed by tumour epithelial cells such as Smad4 (Tascilar et al,
2001; Biankin et al, 2002; Blackford et al, 2009; Iacobuzio-Donahue
et al, 2009), or patterns of stromal fibroblast-expressed proteins
such as Sparc have been shown to predict outcome (Sato et al,
2003; Infante et al, 2007).
Vimentin is expressed by normal mesenchymal tissue and is
considered a marker of mesenchymal differentiation (Leader et al,
1987). Vimentin is an intermediate-sized filament polypeptide,
which along with desmin, keratin, glial acidic protein and
neurofilament intermediate filaments are distinguished by their
chemical characteristics, immunological specificities and cell-type
distribution (Dellagi et al, 1983; Lazarides et al, 1982). Epithelial
neoplasms can occasionally express both cytokeratin and vimentin,
features often associated with the acquisition of mesenchymal
histologic features. There is evidence that carcinomas with
markers of mesenchymal differentiation have different biological
and clinical behaviour (Domagala et al, 1990a,b; Medeiros et al,
1988; Liu et al, 2010). Pancreatic cancer vimentin expression
patterns have been investigated in small series. Schussler et al
(1992) reported a lack of expression in pancreatic cancers, while
Nakajima et al (2004) observed sparse cell labelling in 30 primary
pancreatic adenocarcinomas with prominent expression in 15 liver
metastases. Similarly, vimentin labelling was more pronounced in
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swidely metastatic pancreatic cancers as compared with locally
destructive ones (Naito and Iacobuzio-Donahue, 2010). Khoury
et al found that vimentin expression in 34 pancreatic cancers
correlated with poor survival (Javle et al, 2007). Interestingly,
although mesenchymal differentiation is associated with reduced
E-cadherin expression in vitro, in liver metastasis of pancreatic
ductal adenocarcinomas Nakajima et al (2004) found a correlation
between vimentin expression and N-cadherin but not E-cadherin
expression. More recent reports suggest that, in vitro, most
pancreatic cancers with well-defined glandular differentiation do
not show the downregulation of E-cadherin, although focal loss of
E-cadherin expression is observed in some primary pancreatic
cancers (Li et al, 2010; Hong et al, 2011 (in press)) and
undifferentiated pancreatic cancers often display complete loss of
E-cadherin expression (Winter et al, 2008).
In this study, we investigated vimentin expression in a large
series of pancreatic ductal adenocarcinomas treated by surgery
and assessed its relationship to survival.
PATIENTS AND METHODS
Patients and samples
Patients having conventional pancreatic ductal adenocarcinoma
(Kloppel et al, 2000), treated by surgical resection were retrieved
from the database of the Pathology Department, of the Johns
Hopkins Medical Institutions, Baltimore, MD, USA. Between 1998
and 2006, 387 patients had available neoplastic tissue blocks to
construct tissue microarrays.
This study was designed and performed according to current
recommendations for tumour markers (McShane et al, 2005). The
patients were analysed for clinical and pathological data according
to standard criteria (Kloppel et al, 2000; AJCC, 2010). The clinical
data analysed included: age, gender, date of surgery, type of
surgery, stage, date of death or last consultation for the
postsurgical survival. As information on adjuvant therapy was
not complete for some patients who received their postoperative
therapy at other centres, postoperative therapy was not included in
the analysis of the prognostic significance of vimentin. The
analysed pathological data were: tumour size, histological differ-
entiation, vascular invasion, perineural invasion, pathological T
TMN stage, lymph node metastases and N TMN stage as well as for
distant metastases (M TNM stage). As their outcome is signifi-
cantly different patients were excluded if they had a peri-operative
death (occurring within the first 30 days postoperatively, 4
patients) or with follow-up of o30 days (28 patients), a distal
splenopancreatectomy (1 patients) or if they received neoadjuvant
radiotherapy (2 patients).
Immunohistochemistry
Vimentin protein expression was assessed in the tumour epithelial
tissues by immunohistochemistry. Tissue microarrays were con-
structed from representative areas of neoplastic epithelial cells and
normal pancreas as previously described (Infante et al, 2007;
Matsubayashi et al, 2007; Walter et al, 2010). Each patient’s tissue
was represented on the tissue microarrays by two cores of
pancreatic cancer and two cores of non-neoplastic pancreas.
Immunohistochemistry was performed using an antibody to
vimentin protein (Dakocytomation, Carpinteria, CA, USA, clone
V9, dilution 1:200). Protein expression in the cytoplasm or peri-
membrane and membrane in epithelial malignant cells setting was
assessed by an experienced pancreatic pathologist (AHL) at an
Olympus BX51 microscope (Olympus, Center Valley, PA, USA).
The percentage of labelled tumour epithelial cells was determined.
Spindle-shaped isolated cells with bland, regular nucleus were
considered as stromal fibroblasts. Representative neoplastic zones
were photographed and were included in the figures (Photo
Olympus DP20). For 14 patients, there were no data on vimentin
neoplastic cell expression because of tissue loss during the
immunolabelling protocol. For each neoplasm, the core with the
highest expression of vimentin was taken into consideration for
subsequent statistical analysis. The percentage of labelled neo-
plastic epithelial cells ranged from 0 to 95%.
Statistical analysis
For the statistical analysis, the variables were considered as
categorical. For continuous variables such as tumour size or lymph
node metastases, the cutoff for classifying the tumours was the
median. We also determined the median percentage of vimentin-
expressing neoplastic cells, which was 1% and used this as a cutoff
for classifying cancers. We also evaluated other cutoffs (0, 10, 20, 30,
40, 50, 60, 70, 80 and 90%). According to the distribution of the
percentage of vimentin-expressing neoplastic cells in this series of
tumours, the cutoff of 10% was accepted as most predictive. The
relationships between clinico–morphological variables and the
expression of vimentin by neoplastic cells were analysed by using
the Fisher’s or w
2-tests (Medcalc v11.1.1 software, Medcalc,
Mariakerke, Belgium). For univariate survival analysis we used the
Kaplan–Meier method, the survival curves being compared by the
log-rank test. For multivariate survival analysis we used the Cox
method. Variables found on univariate analysis to be related to
postsurgical survival with a P-value of o0.05 were included in Cox
models. Colinearity (redundancy) of variables being significantly
correlated on Fisher’s or w
2-tests was tested (neoplastic differentia-
tion and vimentin expression, microscopic vascular expression and
lymph node metastases, tumour size and type of surgery). Patients
with unavailable data were included in the analysis as ‘unknown’.
For all the statistical tests and methods, a P-value of o0.05 was used
for defining statistical significance (Christensen, 1987; Chen and
Wang, 1991; Hosmer and Lemeshow, 2000).
RESULTS
Patients’ and tumour characteristics
The patients’ demographics are listed in Table 1. The median follow-
up was 14.4 months (range, 1.1–101.95 months). During the study
period, 246 patients died (excluding patients with perioperative
death) and the median survival was 14.4 months and the time to
death was 12.90 months (range, 1.21–59.24 months). The 3-year
postsurgical survival was 19.32% and the 5-year survival 8.0%.
Median tumour size was 30mm (range, 10–120mm). Tumour
size was significantly higher in those patients having total
pancreatectomy surgery as compared with those treated by
pancreaticoduodenectomy (P¼0.04). Lymph node metastases
were observed in 85.7% of the patients with the median number
of metastatic lymph nodes being 3 (range, 1–25). The presence of
lymph node metastases was correlated to vascular and perineural
invasion (Po0.01 and P¼0.05, respectively), whereas presence of
43 lymph node metastases was correlated to vascular invasion
and increased neoplastic size (Po0.01 and P¼0.02, respectively).
Three patients showed distant metastasis (pericaval, mesocolon
and subcostal skin metastases, respectively).
Vimentin expression by pancreatic cancer cells
Vimentin expression by the neoplastic cells was observed in 154
(45%) pancreatic ductal adenocarcinomas (Figure 1), and included
a wide variation in the extent of cancer cell expression varying
from 1 to 95%, with the median percentage of vimentin-labelled
cancer cells being 1%. In 94 pancreatic cancers (27.5%), vimentin
was expressed in 410% of neoplastic cells. There was not a
specific labelling pattern, vimentin being expressed by cells with
varying degrees of cytonuclear atypia, with or without intracellular
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within the stroma. When analysed with regard to the morpholo-
gical features of the neoplasm, the expression of vimentin by
neoplastic cells was significantly correlated only with poor
histological differentiation (using the vimentin cutoff of 1%, 76
of 148 poorly differentiated cancers compared with 78 of 194 well
and moderately differentiated cancers; using the vimentin cutoff of
10%, 53 of 143 poorly differentiated neoplastic cells vs 41 of 194
well and moderately differentiated cancers) (P¼0.05 and Po0.01
for vimentin cutoffs 1% and 10%, respectively). There was no
statistical difference in neoplastic cell vimentin expression between
early-stage (stages T1 or T2 TNM) and advanced tumours (TNM
stages T3 or T4). By univariate survival analysis (Table 1), patients’
outcome was correlated with poor histological differentiation,
positive tumour resection margins, the presence of lymph node
metastases, increased tumour size and tumour epithelial vimentin
expression. The statistical significance of the relationship between
tumour epithelial vimentin expression and a shorter postsurgical
survival was more important when considering the cutoff of 10%
(Po0.01, median postsurgical survivals 12.49 vs 19.72 months)
(Figure 2) than for the cutoff of 1% (P¼0.02, median postsurgical
survivals 15.05 vs 19.52 months). By multivariate survival analysis
(Table 2), tumour epithelial vimentin expression was significantly
related to a shorter postsurgical survival, independently of the
degree of histological differentiation, surgical margin status,
tumour size (430mm) and lymph node metastases. In this model,
high (410%) tumour epithelial vimentin expression was a more
powerful predictor of outcome than the N TNM stage, the type of
surgery, and tumour size, the risk of death being 1.53.
High tumour epithelial vimentin expression correlated with
3- and 5-year survival (Po0.01 for both comparisons) as well as
tumour size (P¼0.03 and P¼0.05), N TNM stage (Po0.01 and
P¼0.03), differentiation (Po0.01 for both comparisons), surgery
type (P¼0.03 and P¼0.05), and margin status (Po0.01 and
P¼0.02).
The association of positive vimentin expression with a shorter
survival remained among the main subgroups of patients studied
including those treated by pancreaticoduodenectomy, with T3
stage cancers, those patients with lymph node metastasis (N1 TNM
stage) and those patients having margin negative, stage 2 or stage
2B disease or in those patients having cancers with moderate or
poor differentiation (Table 3) (Figure 3).
Similarly, in the group of patients having cancers with high
vimentin expression (410% of cancer cells expressing), margin-
positive surgical resection (P¼0.04) and tumour size (P¼0.04)
were also predictors of a shorter postsurgical survival.
DISCUSSION
Our analysis of a large series of pancreatic adenocarcinomas
treated by surgical resection indicated that tumour epithelial
Table 1 Clinico–pathological characteristics of the patients with
pancreatic ductal adenocarcinomas treated by surgical resection
Number of
patients
n¼356
a
Median
postsurgical
survival (months)
Log-rank
P
Gender 0.83
Women 160 16.76
Men 196 18.08
Age (years)
Range 32–90
Median 66.66
Outcome
Follow-up 14.4
Range, months 1.08–101.95
Median, months 14.4
Dead 246
Alive 110
T Stage 0.12
pT1 4 —
pT2 7 17.44
pT3 336 17.98
pT4 9 10.29
Differentiation o0.01
Well, moderate 199 21.89
Poor 157 13.01
Vascular invasion 0.02
Absent 170 20.38
Present 176 15.32
Indeterminate 10 12.82
Surgery type 0.04
Pancreaticoduodenectomy 335 17.98
Total pancreatectomy 21 10.75
Tumour size 0.02
Range, median
30mm 217 19.59
430mm 139 14.66
Surgical margins o0.01
Non-tumoral 238 20.31
Tumoral 118 14
Lymph node metastasis
N TNM stage 0.01
N0 51 26.4
N1 305 16.63
Abbreviations: n¼number of patients; N¼node; T¼tumour; p¼pathology;
TNM¼tumour node metastasis classification.
aPatients with perioperative death
(within the 30 days after surgery), were not included for the statistical analysis.
Figure 1 Vimentin protein expression in primary pancreatic adenocarcinoma cells: the figure on the left (A) shows minimal vimentin expression in a few
pancreatic cancer cells (arrow), vimentin also being expressed in stromal fibroblasts (considered as internal control, arrowheads). On the right side (B) there
is pancreatic adenocarcinoma showing uniform cytoplasmic and perimembrane pattern of vimentin expression (arrow) (original magnification  30).
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svimentin expression is an indicator of adverse outcome both on
univariate and multivariate survival analysis, independently of
classical tumour characteristics such as differentiation, tumour
size, resection margin status and type of surgical treatment.
The most powerful predictors of a shorter postsurgical survival
in our series were positive margin status and poor histological
differentiation, in agreement with the results of Herman et al
(2008), and Winter et al (2006), in previous studies from our
institution. We also found that lymph node metastasis predicted a
shorter postsurgical survival, consistent with already reported
results (Winter et al, 2006; Infante et al, 2007; Chang et al, 2009).
Vimentin expression by neoplastic cells was observed in 45% of
the pancreatic adenocarcinomas and an expression level of 410%
was noted in 27.5% of the pancreatic cancers. We found this 10%
cutoff to be more predictive of outcome than other cutoffs of
percentage expression or the absolute cutoff (of presence vs
absence of neoplastic cell expression). Although the expression
concerned a limited percentage of neoplastic cells in some
tumours, vimentin was significantly related to postsurgical
survival. The association of vimentin expression to a shorter
survival had a greater prognostic significance than that of N TNM
stage, tumour size, and of almost as much magnitude as other
prognostic factors such as differentiation and surgical margin
(Winter et al, 2006; Herman et al, 2008; Chang et al, 2009).
The underlying biological mechanisms that might explain the
relationship between vimentin and survival are not known. As has
been previously reported for breast and prostatic adenocarcinomas
(Domagala et al, 1990a,b; Heatley et al, 1993; Zhao et al, 2008), we
found a correlation between vimentin expression and histological
differentiation. Previous studies have found associations between
vimentin expression and cancer cell morphology in tumour
xenografts (Neureiter et al, 2005). Vimentin expression in
neoplastic epithelial cells might reflect a reorganisation of
cytoplasmic intermediate filaments, which could be related to
poor differentiation. However, poor differentiation is more
complex than cytoplasmic changes since it involves also nuclear
changes. Although vimentin expression is associated with poor
differentiation in cancers, in our series vimentin expression is still
an independent predictor of outcome after accounting for the
degree of differentiation suggesting vimentin expression is a
marker for more than differentiation. Whether or not vimentin
expression directly affects the aggressiveness of pancreatic cancer
cells because of its functional effects as an intermediate filament or
whether it is merely a marker of a more aggressive cancer cell is
not known. Studies of peripheral blood mononuclear cells as well
as of human breast, colon and prostate cancer cell lines suggest a
cell-type-specific role for vimentin in cell adhesion, motility and
invasiveness (Nieminen et al, 2006; Ivaska et al, 2007; McInroy and
Ma ¨a ¨tta ¨, 2007; Zhao et al, 2008). Vimentin’s functions are
influenced by cell signalling pathways such as AKT and STK33
that result in vimentin phosphorylation (Ivaska et al, 2007;
Brauksiepe et al, 2008; Zhu et al, 2011). Vimentin phosphorylation
contributes to disassembly of vimentin polymers diminishing
its function as an intermediate filament and influencing its
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Figure 2 Kaplan–Meier curves for postsurgical survival according to tumour epithelial vimentin expression when considering the cutoff of 1% (A) and
that of 10% (B). The continuous line indicates the patients with high vimentin (41o r410%) expression whereas the discontinuous lines those patients
with low vimentin expression.
Table 2 Cox model including as variables tumour and surgical resection
parameters
P-value
Hazard
ratio
95% confidence
interval
Differentiation o0.01 1.54 1.20 to 1.96
Surgical margin status o0.01 1.62 1.24 to 2.12
Tumour vimentin expression o0.01 1.53 1.14 to 2.05
Type of surgery 0.03 1.81 1.07 to 3.08
N TNM stage 0.05 1.48 1.00 to 2.18
Tumour size, 43mm 0.14 1.22 0.94 to 1.59
Abbreviations: N¼node; TNM¼tumour node metastasis classification.
Table 3 Univariate survival analysis for vimentin expression in pancreatic
ductal adenocarcinomas
Median postsurgical
survival (months)
Log-rank
P-value
Patients treated by pancreaticoduodenectomy (n¼322) o0.01
Low tumour vimentin 19.72
High tumour vimentin 12.82
T3 TNM stage patients (N¼322) o0.01
Low tumour vimentin 20.35
High tumour vimentin 12.49
N1 TNM stage patients (N¼293) o0.01
Low tumour vimentin 19.29
High tumour vimentin 12.09
Stage 2 patients (AJCC 7) (N¼328) o0.01
Low tumour vimentin 20.38
High tumour vimentin 12.49
Stage 2B patients (AJCC 7) (N¼279) o0.01
Low tumour vimentin 20.35
High tumour vimentin 12.29
Patients with margin negative surgical resections (N¼230) 0.02
Low tumour vimentin 14.95
High tumour vimentin 10.25
Patients having tumours with moderate or poor histological differentiation
(N¼332)
o0.01
Low tumour vimentin 19.46
High tumour vimentin 12.49
Abbreviations: AJCC¼American Joint Committee on Cancer; n¼number of
patients.
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by caspases when cells receive pro-apoptotic stimuli (Lahat et al,
2010). Recently vimentin has evolved as a marker of ‘epithelial–
mesenchymal transdifferentiation’ and many molecular alterations
have been implicated in this process including Notch, miR-200 and
others (Klymkowsky and Savagner, 2009). Cancer cell vimentin
expression has also been found to influence treatment response
in vitro. For example, gemcitabine-resistant pancreatic cancer cells
display increased vimentin expression (Traub et al, 1985), and
vimentin expression increased in Panc-1 cell lines when treated by
TGFbeta (Nakajima et al, 2004). Vimentin has been investigated as
a therapeutic target. A natural compound, withaferin-A-induced
vimentin degradation and slowed the growth of sarcomas and had
proapoptotic effects in sarcoma and carcinoma cell lines expres-
sing vimentin (Lahat et al, 2010).
In recent years, vimentin expression has been commonly used as
a marker of mesenchymal phenotypes but this intermediate
filament has complex functions including its affinity to single-
stranded and supercoiled DNA and its strong tendency to interact
with different chromatin constituents including histones (Traub
et al, 1985). However, mice lacking vimentin do not have altered
phenotypes so the functional significance of vimentin expression is
not well understood (Colucci-Guyon et al, 1994).
As vimentin is highly expressed in stromal fibroblasts it is not
likely to be useful as a marker for differentiating pancreatic
cancers from pancreatitis, but interestingly autoantibodies to this
protein have been recently reported (Hong et al, 2006). Pancreatic
neoplastic tissues showed a three-fold higher expression of
vimentin than neoplasms of other origins (lung, colon and ovary),
and had higher levels of an isoform with demonstrable immuno-
genicity (Hong et al, 2006). More promising as a marker of
neoplasia is vimentin promoter methylation, which is being
evaluated as a candidate marker of colorectal carcinomas (Chen
et al, 2005; Zou et al, 2007; Shirahata et al, 2009).
There are a number of limitations to our study that should be
acknowledged. First, our study is a single-centre study, and
confirmation of our findings in other series is warranted. Second,
our prognostic model did not include postoperative therapy in our
model as unlike surgical therapy, postoperative therapy is not
uniform in our study population. Although our cases were not
selected with regard to their postoperative course, it is possible
that the association between tumour epithelial vimentin expression
and outcome of pancreatic cancer could be influenced by
differences in postoperative chemoradiotherapy.
In conclusion, the results of our study suggest that de novo
tumour epithelial expression of vimentin in pancreatic ductal
adenocarcinoma is an independent predictor of adverse post-
surgical outcome.
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